Trabectedin is FDA-approved for advanced liposarcoma and leiomyosarcoma and can deplete both macrophages and MDSC through TNF-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis (47–49). Here, TNFSF10 is linked to leiomyosarcoma.